Front. Microbiol. Frontiers in Microbiology Front. Microbiol. 1664-302X Frontiers Media S.A. 10.3389/fmicb.2016.01385 Microbiology Review Nanotechnology: A Valuable Strategy to Improve Bacteriocin Formulations Fahim Hazem A. 1 Khairalla Ahmed S. 2 * El-Gendy Ahmed O. 2 * 1Department of Biotechnology and Life Sciences, Faculty of Post Graduate Studies for Advanced Sciences, Beni-Suef University Beni-Suef, Egypt 2Department of Microbiology and Immunology, Faculty of Pharmacy, Beni-Suef University Beni-Suef, Egypt

Edited by: Andrea Gomez-Zavaglia, Center for Research and Development in Food Cryotechnology, Argentina

Reviewed by: Sergio Enrique Pasteris, National University of Tucumán, Argentina; Mohamed Mahrous Emara, Helwan University, Egypt

*Correspondence: Ahmed S. Khairalla ahmedkhairalla@pharm.bsu.edu.eg

Ahmed O. El-Gendy ahmed.elgendy@pharm.bsu.edu.eg

This article was submitted to Food Microbiology, a section of the journal Frontiers in Microbiology

 16 09 2016 2016 7 1385 29 06 2016 22 08 2016 Copyright © 2016 Fahim, Khairalla and El-Gendy. 2016 Fahim, Khairalla and El-Gendy

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Bacteriocins are proteinaceous antibacterial compounds, produced by diverse bacteria, which have been successfully used as: (i) food biopreservative; (ii) anti-biofilm agents; and (iii) additives or alternatives to the currently existing antibiotics, to minimize the risk of emergence of resistant strains. However, there are several limitations that challenge the use of bacteriocins as biopreservatives/antibacterial agents. One of the most promising avenues to overcome these limitations is the use of nanoformulations. This review highlights the practical difficulties with using bacteriocins to control pathogenic microorganisms, and provides an overview on the role of nanotechnology in improving the antimicrobial activity and the physicochemical properties of these peptides.

 bacteriocin antimicrobial peptides biopreservative nanotechnology nanoformulated bacteriocins drug delivery systems Introduction

Bacteriocins are a group of polypeptides that are produced by a variety of Gram-negative and Gram-positive bacteria, and exhibit bactericidal or bacteriostatic activity, usually against species closely related to the producing strain (Tagg et al., 1976; Castellano et al., 2012; El-Gendy et al., 2013). While they may be categorized as antibiotics, bacteriocins differ in that they are: (i) proteinaceous, ribosomally synthesized, molecules produced during the primary phase of growth; (ii) known to exhibit a relatively narrow spectrum of antibacterial activity; (iii) inactivated by digestive enzymes, which makes them non-toxic to human cells if used as biopreservative; and (iv) unique in their mechanism of action (Tagg et al., 1976; Zacharof and Lovitt, 2012; Balciunas et al., 2013; Perez et al., 2014). Regarding the structure, classification, mode of action, and genetic characterization of bacteriocins, these aspects have been discussed in a number of reviews (Klaenhammer, 1993; Héchard and Sahl, 2002; Nes et al., 2007; Hoover and Steenson, 2014) and will not be covered here.

Over the last decade, bacteriocins have gained considerable attention due to their potential applications in the food industry as natural biopreservatives, and more recently in the health industry as antimicrobial agents (Zacharof and Lovitt, 2012; El-Gendy et al., 2013). Regarding the first field of application, bacteriocins can be either added directly as purified (or partially purified) agents to food or produced through cultivation of the bacteriocin-producer strain in the food substrate (Deegan et al., 2006). Among the advantages gained by this approach are: chemical-free preservation, shelf-life extension, and inhibition of food-borne pathogenic bacteria during the farming and food-processing stages (Deegan et al., 2006). Moving to the second field of application, the expanding clinical applications of bacteriocins may help us to fill some gaps in the biomedical sector. For example, some bacteriocins have displayed activity against Gram-positive pathogens of human and animal origin, including methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus faecalis strains (Kruszewska et al., 2004; Millette et al., 2008). This antibacterial activity makes bacteriocins a promising substitute or a synergistic component to the currently used antibiotics to overcome the emergency of bacterial resistance.

However, in spite of these promising advantages, nisin is the only bacteriocin generally recognized as safe by the Food and Drug Administration and is currently used as a food preservative in several countries (Delves-Brougthon, 1990; Montville and Chen, 1998). This limitation in bacteriocins availability in the market as preservatives and antimicrobials can be attributed to multiple factors, including: (i) the high cost of their commercial production (Bradshaw, 2003); (ii) the loss of their activity by proteolytic enzymes (Bradshaw, 2003); (iii) their unfavorable interactions with other food constituents, which decreases the availability and necessitates a huge amount of the peptide to be added (Jung et al., 1992; Schillinger et al., 1996); (iv) the alterations of the chemical and physical properties of these compounds during the various food-processing stages (Davidson et al., 2005); (v) the low yield of these compounds due to ineffective recovery by traditional purification methods (Carolissen-Mackay et al., 1997); and (vi) the narrow spectrum of activity observed for most of the tested bacteriocins against pathogenic bacteria (Riley and Wertz, 2002). In the last years, several studies on bacteriocins have demonstrated that the optimization of their production conditions, their purification methods, their combinations with other antimicrobial agents, and the hurdle technology approach, could all represent solutions to some of the previously mentioned problems (Kalchayanand et al., 1994; Li et al., 2001; Wolska et al., 2012; Saraniya and Jeevaratnam, 2014). While scientists are searching for efficient strategies to overcome the limitations of bacteriocins, the use of nanotechnology is a potential approach to maximize the use of these peptides (Allémann et al., 1998; Salmaso et al., 2004). Therefore, this article aims to elucidate the current applications of nanotechnology in improving the properties and the antimicrobial activity (AMA) of bacteriocins.

 Advantages of nanoformulated bacteriocins

According to the U.K. House of Lords Science and Technology Committee, nanotechnology is the manipulation of functional materials and structures into the nanoscale size (with diameters ranging from 1 to <1000 nm; Klaessig et al., 2011). This is a quite novel technology that has several applications in various fields of science due to the unique features of the synthesized nanoparticles (Chou et al., 2011). The integration of nanotechnology and biotechnology opens the door to unlimited opportunities and future perspectives to solve the problems belonging to a range of biological products. Through this integration, effective delivery, targeting, protection from degradation, in addition to improving drug potency and physicochemical properties can all be achieved (Farokhzad and Langer, 2009). Bacteriocins are one of the many examples that can benefit from such combination. For instance, nano-encapsulation of bacteriocins intended for use as biopreservatives could protect them from degradation by proteolytic enzymes, in addition to rescuing them from undesirable interactions with other food components, and hence, increasing their stability for longer periods (Brandelli, 2012). Furthermore, some recent studies have shown that encapsulation of bacteriocins in nanoparticles has enhanced the activity of these peptides against food-spoiling microorganisms and multidrug-resistant bacteria (Arthur et al., 2014; Mossallam et al., 2014). In addition, the use of nanotechnology-based materials and/or methods has, in most cases, shown a positive impact on bacteriocin yield, thus facilitating their commercial production (Zacharof et al., 2013). Table 1 illustrates several examples of bacteriocins that have been formulated using nanotechnological approaches, while Figure 1 summarizes the major benefits form such formulations. However, it must be stated that some of the nanoformulated bacteriocins have nearly the same activity (or even lower) compared with the free ones (da Silva Malheiros et al., 2012a; Malheiros Pd et al., 2012), which will be explained below in more details.

Examples of bacteriocins that have been formulated using nanotechnological approaches.

Bacteriocin Nanotechnological approach Fabrication method Characters of the resulting nanoformulation Tested microorganism(s) Effect(s) of nanoformulation References
Particle size Entrapment efficiency (%)
BLS P40 produced by Bacillus licheniformis Phosphatidylcholine nanovesicles Reverse phase evaporation method 570 nm NR Listeria monocytogenes Maintained the AMA for a longer period Teixeira et al., 2008
BLS P34 Phosphatidylcholine nanovesicles Thin-film hydration method 160 nm 100% L. monocytogenes Both the free and the encapsulated bacteriocins had nearly the same AMA da Silva Malheiros et al., 2012a
Bacteriocin produced by Lactobacillus plantarum ATM11 and nisin Gold nanoparticles NR NR NR Bacillus cereus, Escherichia coli, S. aureus, and Micrococcus luteus Enhanced the AMA against some food spoiling microorganisms Thirumurugan et al., 2013
Enterocin Silver nanoparticles NR 325 nm NR A group of Gram-positive and Gram-negative bacteria Demonstrated broad-spectrum inhibition against a group of food pathogens without any detectable toxicity to red blood cells (RBCs) Sharma et al., 2012
Bacteriocin produced by Lactobacillus acidophilus CH1 Gold nanoparticles NR 20.15 nm NR Enterocytozoon bieneusi spores Increased the anti-microsporidial effect without significant cell toxicity Mossallam et al., 2014
Nisin Phosphatidylcholine Nanoliposomes NR 144, 167, and 223 nm depending on the type of nanoliposomes 54–63% NR Nisin entrapped efficiently in nanoliposomes Were et al., 2003
Nisin Nanoliposomes NR Different particle size due to differences in preparation methods 70–90% NR Provided stability to a wide range of temperature conditions Taylor et al., 2007
Nisin Phosphatidylcholine nanoliposomes Reversed-phase and hydration film methods 190, 181 and 148 nm depending on the preparation method 94.12% with film hydration method L. monocytogenes The free nisin was more potent and exhibited more sustained release compared to the encapsulated one da Silva Malheiros et al., 2010a
Nisin Phosphatidylcholine nanoliposomes Thin-film hydration method 140 nm 100% L. monocytogenes The free nisin was more potent than the encapsulated one Malheiros Pd et al., 2012
Nisin A Phosphatidylecholine nanoliposomes Thin-film hydration method 140 nm 94% L. monocytogenes Both the free and the encapsulated bacteriocins had nearly the same AMA at low temperature da Silva Malheiros et al., 2010b
Nisin and BLS P34 Phosphatidylecholine nanoliposomes Thin-film hydration method 218 nm for nisin, and 158 nm for BLS P34 88.9% for nisin and 100% for BLS P34 L. monocytogenes Displayed higher AMA da Silva Malheiros et al., 2012b
Nisin Z Nanoliposomes NR Different particle size (190–295 nm) depending on the type of nanoliposome 12–54% Bacillus subtilis and Pseudomonas aeruginosa Exhibited stability for several months Colas et al., 2007
Nisin Solid lipid nanoparticles (SLN) High pressure homogenization 159–175 nm depending on the concentration of nisin 69.2–73.6% L. monocytogenes and L. plantarum Extended the AMA for a longer duration Prombutara et al., 2012
Nisin Chitosan / alginate nanoparticles NR 50–205 nm 90–95% S. aureus Maximized and prolonged the AMA with minimum concentration of nisin Zohri et al., 2010
Nisin Chitosan / alginate nanoparticles NR 205 nm NR L. monocytogenes ATTC 25923 and S. aureus ATTC 19117 Enhanced the AMA to a higher extent with less damaging effect on the tested food samples Zohri et al., 2013
Nisin Chitosan / carageenan nanocapsules Ionic complexation method 397.6–1106 nm 53–93.32% Micrococcus luteus MTCC 1809, P. aeruginosa MTCC 424, Salmonella enterica MTCC 1253, and Enterobactor aerogenes MTCC 2823 Demonstrated long-lasting AMA Chopra et al., 2014
Nisin Tripolymeric nanoformulation prepared from chitosan, sodium alginate and pluronic F68 Ionotropic pre-gelation method followed by polycationic crosslinking 130–178 nm 41.45–88.36% M. luteus MTCC 1809, P. aeruginosa MTCC 424, S. enterica MTCC 1253 and Enterobactor aerogenes MTCC 2823 Encapsulated nisin released in a sustained manner and displayed AMA for a longer period Bernela et al., 2014
Nisin Carbohydrate nanoparticles NR NR NR L. monocytogenes Extended the AMA for a longer period of time Bi et al., 2011a
Nisin Carbohydrate nanoparticles Adsorption of nisin to emulsion of nanoparticles 336 and 50.2 nm depending on the type of phytoglycogen NR L. monocytogenes Retained the efficacy for a longer period of time Bi et al., 2011b
Nisin Nanofibers Electrospining process 330 ± 79 nm NR S. aureus Prolonged the antimicrobial activity against skin infection and accelerated the wound healing Heunis et al., 2013
Nisin Nanofibers Electrospinning process 200–250 nm NR A strain of MRSA Increased the AMA in presence of 2,3-dihydroxybenzoic acid Ahire and Dicks, 2015
Nisin Nanofibers with Silver nanoparticles Electrospinning process 288 ± 63 nm NR S. aureus, P. aeruginosa, Klebsiella pneumonia, E. coli, and S. typhimurium. Provided a broad spectrum AMA Ahire et al., 2015
Nisin Poly-L-lactide (PLA) nanoparticles Semi-continuous compressed CO2 anti-solvent precipitation 200–400 nm depending on the concentration of nisin About 95% Lactobacillus delbrueckeii Extended the AMA for a longer duration Salmaso et al., 2004
Pediocin Phosphatidylecholine nanoliposomes Thin-film hydration method with bath-type sonicator 190 nm 80% L. monocytogenes Encapsulated pediocin maintained the AMA for a longer period of time, but the free one was more potent de Mello et al., 2013
Plantaricin 423 Nanofibers electrospining Electrospining process 288 nm NR Lactobacillus sakei, and Enterococcus faecium Decreased the AMA Heunis et al., 2010
Plantaricin 423 and bacteriocin ST4SA Nanofibers electrospining Electrospining process 200–450 nm NR E. faecium and L. monocytogenes Displayed higher AMA for a longer period Heunis et al., 2011
The antimicrobial peptide P34 Nanoliposomes Thin-film hydration method 150 nm 100% L. monocytogenes Both the free and the encapsulated P34 showed nearly the same AMA da Silva Malheiros et al., 2011

BLS: bacteriocin-like substance; NR: not reported by authors.

Schematic representation showing some of the nanotechnological approaches used in bacteriocin formulations with their associated characters. 35, da Silva Malheiros et al., 2012a; 41, da Silva Malheiros et al., 2012b; 46, de Mello et al., 2013; 69, Zohri et al., 2010; 70, Zohri et al., 2013;71, Bernela et al., 2014; 72, Chopra et al., 2014; 33, Mossallam et al., 2014; 80, Thirumurugan et al., 2013; 87, Sharma et al., 2012; 94, Heunis et al., 2013; 95, Heunis et al., 2011; 100, Ahire and Dicks, 2015; 101, Ahire et al., 2015.

 Nanotechnological approaches used in bacteriocin formulations Encapsulation in lipid-based nanoparticles Nanoliposomes

Liposomes are spherical structures composed of single or multiple phospholipid bilayer membranes enclosing an aqueous medium with a size ranging from nanometer to micrometer (Bangham et al., 1965; Vemuri and Rhodes, 1995). Besides being non-toxic, liposomes are biodegradable agents suitable for encapsulating both hydrophilic and hydrophobic substances (Gundermann and Schumacher, 1990; Kulkarni et al., 1995). Especially when prepared at the nano size, nanoliposomes represent a promising vehicle for the encapsulation and delivery of several drugs and bioactive compounds, including bacteriocins (Banerjee, 2001; Mugabe et al., 2005; da Silva Malheiros et al., 2012b). For example, phosphatidylcholine-based nanoliposomes have been shown to exhibit high entrapment efficiency (almost 100%) for the bacteriocin-like substance (BLS) P34, without having a negative effect on its antimicrobial activity (da Silva Malheiros et al., 2012a). In another study, nanoliposomes prepared from different lipid/phospholipid compositions and ratios were tested for their: (i) capacity to encapsulate nisin Z; (ii) stability; and (iii) bacterial targeting (Colas et al., 2007). The highest entrapment efficiency for nisin Z (54.2%) has been recorded for nanoliposomes composed of dipalmitoylphosphatidylcholine/dicetylphosphate/cholesterol (DPPC:DCP:CHOL) with 7:2:1 molar ratio (Colas et al., 2007). Additionally, nanoliposomes prepared from DPPC:DCP:CHOL (at 7:2:1 ratio) or from dipalmitoylphosphatidylcholine/stearylamine/cholesterol (at 7:2:1 ratio) have been shown to possess the highest stability, which extended for 14 months at 4°C in case of the former, and 12 months at 25°C in case of the latter (Colas et al., 2007). The results have also shown the ability of nanoliposomes prepared from DPPC:DCP:CHOL to target the outer membranes of Bacillus subtilis (Colas et al., 2007). A study similar to the one just described was conducted by Taylor et al. (2007), in which nanoliposomes prepared from distearoylphosphatidylcholine (PC) and distearoylphosphatidylglycerol (PG) were used to encapsulate nisin. Their results have shown the ability of liposomes consisting of PC, PC/PG (at 8:2), and PC/PG (at 6:4 ratio) to retain about 70–90% of the incorporated nisin with high stability, despite exposure to elevated temperatures (25°–75°C) and acidic or alkaline pH [46]. These findings suggest that the stability of bacteriocins against unfavorable environmental conditions can be improved by nanoliposomal formulations, which still remains to be proved by assessing their AMA (Taylor et al., 2007). A similar study was reported by de Mello et al. (2013), in which pediocin AcH had been successfully loaded with high (80%) entrapment efficiency, stability, and antimicrobial activity, for at least 13 days, when incorporated into phosphatidylcholine nanovesicles (de Mello et al., 2013). However, it must be stated that while the liposome-encapsulated pediocin has been shown to maintain its AMA for a longer period, this activity was lower than that of the free pediocin, which requires further investigations to overcome this issue (de Mello et al., 2013). These collective studies indicate that nanoliposomal formulations of bacteriocins may have distinct capacities to withstand environmental and chemical stresses typically encountered during the different food-processing stages.

Protection from degradation and enhancement of stability are not the only advantages of liposome-encapsulated bacteriocins, as some of these formulations have exhibited better AMA, in terms of either spectrum or duration, which will be discussed in more details in the following paragraph. For instance, phosphatidylcholine nanovesicles containing BLS produced from Bacillus licheniformis P40 have been shown to completely inhibit L. monocytogenes within the first 12 min of incubation (Teixeira et al., 2008). In terms of duration of activity, while the encapsulated BLS has been shown to maintain its initial AMA over 30 days of incubation, it has taken only 14 days for the free one to lose 90% of its activity (Teixeira et al., 2008). In terms of safety, the encapsulated BLS has been shown to lack any hemolytic activity on human erythrocytes, suggesting its safety as food biopreservative (Teixeira et al., 2008). In another study, BLS P34 and nisin were encapsulated individually in nanoliposomal formulations prepared either from phosphatidylcholine alone or phosphatidylcholine/cholesterol (at 7:3 ratio; da Silva Malheiros et al., 2012b). While all the tested formulations have inhibited L. monocytogenes growth, the phosphatidylcholine-based preparations that have been stored for 10 days demonstrated the highest AMA against this bacterium in Minas frescal cheese samples (da Silva Malheiros et al., 2012b). Therefore, phosphatidylcholine nanovesicles seem to promote the slow release of the incorporated bacteriocins, which explains the storage duration required to exert their efficacy against target microorganisms (da Silva Malheiros et al., 2012b).

However, in spite of the above encouraging examples, encapsulated bacteriocins with activity similar to, or less than, the free ones have been reported in few other studies (da Silva Malheiros et al., 2012a; Malheiros Pd et al., 2012). For example, when nisin has been encapsulated in phosphatidylcholine nanoliposomes, the encapsulated and the free nisin had both displayed nearly equal antilisterial activities (da Silva Malheiros et al., 2010a). Additionally, while the free nisin has been shown to maintain its AMA over 24 days of incubation, the activity of the encapsulated one has declined to 25% of its initial levels after only 10 days of storage (da Silva Malheiros et al., 2010a). Another example is the study of Malheiros Pd et al. (2012), in which nisin encapsulated in phosphatidylcholine nanoliposomes has only displayed a bacteriostatic effect against L. monocytogenes in Minas frescal cheese, whereas the free nisin has exhibited a bactericidal effect under the same conditions (da Silva Malheiros et al., 2010a). This negative impact on bacteriocin AMA may be attributed to: (i) selection of unsuitable phospholipid-bacteriocin combinations; (ii) undesirable interactions between the bacteriocin and the phospholipid forming the liposome; (iii) stresses applied during the encapsulation process; and/or (iv) low-purity level of the starting materials, including the antimicrobial peptide itself (Were et al., 2003; da Silva Malheiros et al., 2010a,b). Therefore, further studies are required to optimize the formulation of bacteriocin-loaded liposomes, in order to avoid the negative impacts mentioned above.

 Solid lipid nanoparticles (SLN)

Another example of lipid-based formulation systems is SLN, in which each nanoparticle is composed of a triglyceride core with a phospholipid coat of high-melting point, which is responsible for keeping them in a solid state, both at room and human body temperatures (Puri et al., 2009). In addition to the multiple advantages of liposomes, the solid core possessed by SLN makes them powerful tools for large-scale production and slow-release drug formulations (Feng and Mumper, 2013). In a recent study, the release of nisin incorporated into SLN carrier has continued for about 25 days, depending on the pH and the salt concentration of the buffer solution (Prombutara et al., 2012). Additionally, nisin-loaded SLN have demonstrated activity against L. monocytogenes DMST 2871 for up to 20 days and activity against L. plantarum TISTR 850 for up to 15 days, while the activity of free nisin lasted only for 3 days against the former organism and for 1 day against the latter (Prombutara et al., 2012). This indicates that SLN have the ability to protect bacteriocins from degradation, and hence extend their antibacterial activity for a longer period of time. However, the use of SLN as a delivery system for bacteriocins is still in the early exploratory phases of research. Furthermore, there are a number of challenges that need to be overcome to fully establish the SLN as a delivery system; these challenges include the possible expulsion of the incorporated drug/drug-like agents from the lipid matrix and the low drug-loading capacity (Jenning et al., 2000; Souto et al., 2006).

 The use of carbohydrate-based nanoparticles Chitosan/alginate nanoparticles

Carbohydrates are naturally occurring organic substances that serve both structural and storage functions (Ghazarian et al., 2011). They are biodegradable, biocompatible substances, with highly stable properties, and thus have attracted much attention for their applications in the food, biomedical and environmental fields (Chen and Soucie, 1985; Jizomoto et al., 1993; Richardson et al., 1999; Melamu and Von Blottnitz, 2009). Chitosan, a natural biopolymer produced by the deacetylation of chitin, is one of the most commonly used polysaccharides for fabrication of nanoparticles (Nitta and Numata, 2013). In addition to being non-toxic, biodegradable, and biocompatible, chitosan is characterized by its antibacterial activity, together with its ability to deliver drug molecules and biological compounds to their target destination (Richardson et al., 1999; Jia et al., 2001). For example, chitosan nanoparticles have demonstrated high efficiency for the delivery of diverse compounds, such as insulin, genes, vaccines, and other molecules (Vila et al., 2004; Lavertu et al., 2006; Li et al., 2009; Zhang et al., 2010). The combination of chitosan and alginate has been shown to improve the characters of both polymeric components and to provide better delivery than that obtained by using each biopolymer separately (Murata et al., 1993; Sezer and Akbuga, 1999). Such combination has been successfully used to encapsulate nisin, with 95% entrapment efficiency (Zohri et al., 2010). The encapsulated nisin has been found to be released in high concentrations within the first 4 h, followed by a steadily sustained release for more than 5 h (Zohri et al., 2010). Regarding its biological activity, the nisin-loaded chitosan/alginate has exhibited a much higher level of AMA (about 2-folds higher) than that of the free nisin, when tested against S. aureus ATCC 19117 (Zohri et al., 2010). Also, the minimum inhibitory concentration (MIC) of the nisin-loaded nanoparticles has been shown to be four times less than that of the free nisin (0.5 and 2 mg/ml, respectively; Zohri et al., 2010). Additionally, the nisin-loaded nanoparticles have shown significant growth-suppressing effects on S. aureus in both raw and pasteurized milk samples, which remained for at least 24 and 48 h, respectively, compared to 14 and 24 h in case of the free nisin (Zohri et al., 2010). These promising results have been emphasized in another study performed by Zohri et al. (2013). In their study, the nisin-loaded chitosan-alginate nanoparticles have shown a higher level of AMA against L. monocytogenes and S. aureus compared with the free nisin (Zohri et al., 2013). Furthermore, this nano-polymer hybrid did not affect the physicochemical characters of the tested food material (Zohri et al., 2013). Similar studies have demonstrated the efficiency of chitosan-based delivery systems for bacteriocins (Bernela et al., 2014; Chopra et al., 2014). Among the advantages provided by using this type of nanodelivery systems are: the potent, long-lasting AMA, the sustained-release characteristics of the system, and the maintenance of original food quality (Bernela et al., 2014; Chopra et al., 2014). Therefore, it can be concluded that harnessing of these biocompatible nanoparticles in the food industry is a promising strategy for delivery of natural food preservatives in high efficiency with fewer undesirable effects.

 Phytoglycogen nanoparticles

Phytoglycogen is a polysaccharide material found in plants, which is commonly used for preparing novel functional nanoconstructs (Chen et al., 2015). In addition to chitosan that has been discussed earlier, phytoglycogen and its derivatives represent another class of carbohydrate-based nanoparticles that have been successfully used as carriers for nisin (Bi et al., 2011a). When the capabilities of different phytoglycogen derivatives have been examined as carriers of nisin, all the derivatives have demonstrated a long-lasting AMA against L. monocytogenes, but the longest activity has been associated with octenyl succinate and β-amylolysis substitutions (Bi et al., 2011a). Both phytoglycogen derivatives have retained the activity of nisin against common food pathogenic bacteria for 21 days, in comparison with 7 days in case of the free nisin (Bi et al., 2011a). In a similar study, phytoglycogen octenyl succinate has been effectively used to form an oil-in-water emulsion for delivering nisin against L. monocytogenes (Bi et al., 2011b). The antibacterial activity of this nanoparticle-stabilized emulsion has been higher than that of the free nisin during 50 days of storage (Bi et al., 2011b). Overall, these results encourage researchers to exploit nanomaterials as carriers for bacteriocins, which may be especially beneficial to the food industry, to ensure the safety of food both at the packaging stage and after opening the package.

 Conjugation with nanosized metals Conjugation with gold nanoparticles

Metal nanoparticles as gold, silver, copper, zinc have shown potent AMA against pathogenic bacteria (Yoon et al., 2007; Kuo et al., 2009; Raghupathi et al., 2011). Generally, this is due to the large surface area of these positively charged nanoparticles, which facilitates their binding to the negatively charged bacterial membrane (Seil and Webster, 2012). The targeted bacteria are then killed by the oxidative stress induced by the generated reactive oxygen species, together with the toxicity of the accumulated free metal ions (Seil and Webster, 2012). This proposed mechanism of action sets metal nanoparticles as a promising approach to solve the problem of antimicrobial resistance. Therefore, combinations of bacteriocins and nanosized metals are expected to have a synergistic effect on antibacterial properties (Thirumurugan et al., 2013). In a recent study, conjugates containing gold nanoparticles with either nisin or a bacteriocin produced by L. plantarum ATM11 have both displayed significant AMA compared with the free bacteriocins, especially against M. luteus, B. cereus, E. coli, and S. aureus (Thirumurugan et al., 2013). This demonstrates the efficiency of such combinations in extending the shelf-life of food products by inhibiting a number of common food-spoilage microorganisms. In a similar study, incorporation of a bacteriocin produced by L. acidophilus CH1 with gold nanoparticles has resulted in a formulation with potent activity against intestinal microsporidiosis in immunocompromised mice (Mossallam et al., 2014). This bacteriocin-gold nanoconjugate has displayed 89.7% reduction in the number of infected intestinal cells and 93.65% reduction in the number of fecal spores, in comparison with 73.5 and 81.29%, respectively, for the free bacteriocin (Mossallam et al., 2014). In addition, the activity of incorporated bacteriocin has been sustained (with 94.26% efficiency) up to 1 week after the end of the treatment (Mossallam et al., 2014). Furthermore, this nanoconjugated bacteriocin has been shown to be safe and non-toxic, as demonstrated through behavior examinations, biochemical analysis, and histopathological screening tests (Mossallam et al., 2014).

 Conjugation with silver nanoparticles

Silver nanoparticles are used in several applications, ranging from coating medical devices, wound dressing, coating textile fabrics, to water treatment and filtration (Furno et al., 2004; Rujitanaroj et al., 2008; Zhang et al., 2009; Dankovich and Gray, 2011). This is attributed to the broad-spectrum antimicrobial activity possessed by these nanoparticles against most clinically relevant organisms, including drug-resistant pathogens (Lara et al., 2010; Zinjarde, 2012). However, maximizing the antimicrobial efficacy of silver nanoparticles could be achieved by conjugating them to antimicrobial agents, such as bacteriocins. This approach has been demonstrated in a study conducted by Sharma et al. (2012), in which enterocin-capped silver nanoparticles (En-SNPs) have exhibited excellent efficiency against a wide range of Gram-positive and Gram-negative pathogenic bacteria. The highest level of activity of this En-SNPs has been shown against three of the most common food poisoning organisms, namely E. coli, L. monocytogenes, and S. aureus (Sharma et al., 2012). The MIC values of this En-SNPs have been shown to be 2- to 16-fold lower than that of citrate-capped silver nanoparticles (C-SNPs) (Sharma et al., 2012). Furthermore, different concentrations of En-SNPs have shown virtually no hemolytic effects against human RBCs (Sharma et al., 2012). Such results strongly motivate researchers to investigate the antibacterial activity of other bacteriocins-silver nanoparticles conjugates. However, more toxicological studies are needed to demonstrate the safety of these conjugates (Oberdörster et al., 2005).

 Incorporation into polymeric nanofibers

Nanofibers are extremely fine threads that are formed by spinning a polymer solution using a high potential electric field (Anton, 1934). Given their large surface area, small pore size, high physical stability, and powerful encapsulation ability (Doshi and Reneker, 1993; Sharma et al., 2014), nanofibers have attracted much attention as carriers for the target-specific delivery and sustained release of a variety of drugs (Luong-Van et al., 2006; Maretschek et al., 2008). In an application of this approach, an antimicrobial nanofiber wound dressing has been generated by electrospinning nisin into equimolar amounts of poly (ethylene oxide) (PEO) and poly (D, L-lactide) (PDLLA) nanofibers (Heunis et al., 2013). Nisin released from this nanofiber dressing has been shown to: (i) maintain its antistreptococcal activity in vitro for at least 4 days; (ii) remain active, even after storage of the formulation at 4°C for 8 months; (iii) significantly reduce the colonization of S. aureus in a murine excisional skin infection model; (iv) induce an almost complete wound repair, as indicated by the formation of clear fibrotic scar in the group of mice receiving the dressing; and (iv) cause no adverse effects, as revealed by histological analysis of the treated group (Heunis et al., 2013). Another similar study was carried out Heunis et al. (2011), in which nanofibers prepared using different ratios of PEO to PDLLA were used to incorporate plantaricin 423 and bacteriocin ST4SA separately. The release studies showed that a blend of PEO-PDLLA (90:10) resulted in a rapid release of Plantaricin 423 within the first 2 h, followed by a slow and constant release phase that extended for almost 8 days (Heunis et al., 2011). This pattern of release is considered ideal for infection control, since the quickly released bacteriocins will eliminate most of the microbial viable cells within the initial hours of contact, while those slowly released over the following few days are crucial for maintaining the infection under control (Heunis et al., 2011). Similarly, plantaricin 423 and bacteriocin ST4SA released from a blend of PEO-PDLLA (50:50) have been shown to maintain their AMA against sensitive bacterial strains for at least 6 days (Heunis et al., 2011).

Another example of polymeric nanofibers is the Poly-L-lactide (PLA), which is a polymeric biodegradable material that can be used as a drug delivery system once formulated in the nanoscale (Ignatius and Claes, 1996; Perez et al., 2001; Liang et al., 2006). In a study conducted by Salmaso et al. (2004), nisin has been loaded with high capacity into PLA nanoparticles, which offered a sustained-release formulation of the peptide (throughout 1000 h, depending on the pH and the salt concentration of the buffer used). Regarding the biological activity, the nisin-loaded PLA nanoparticles have displayed a potent AMA against L. delbrueckeii lasting up to 45 days, while the activity of the free nisin has been shown to last for 7 days only (Salmaso et al., 2004). These results indicate the usefulness of PLA nanoparticles in providing high stability and sustained release of the incorporated bacteriocin, thereby increasing their applicability in the field of food preservation. However, it must be mentioned that the toxicity of PLA is still controversial (Athanasiou et al., 1996), which requires further research on the biocompatibility of these polymers with different cell types.

Recently, a novel strategy has been implemented to maximize the benefits of bacteriocins in the biomedical field through the exploitation of nanofibers as a delivery system. This strategy depends on the electrospinning of potent bacteriocins and other beneficial substances into nanofibers to target multidrug-resistant bacteria and nosocomial pathogens. As an example of this approach, a study conducted by Ahire et al. (Ahire and Dicks, 2015) has investigated the activity of nisin after being incorporated into nanofibers prepared from PDLLA and PEO with another natural agent, called 2,3-dihydroxybenzoic acid (DHBA). This combination has shown antibiofilm activity against MRSA (Ahire and Dicks, 2015). Biofilm formation decreased by 88% following 24 h of exposure to nanofibers containing nisin and DHBA, compared to a 63% decrease for nanofibers containing only DHBA, and a 3% decrease for nanofibers containing nisin solely (Ahire and Dicks, 2015). The ability of DHBA to chelate free iron, which is needed for biofilm formation, is the proposed mechanism that explains the anti-MRSA biofilm activity (Ahire and Dicks, 2015). In another study, co-incorporation of nisin and silver nanoparticles into nanofibers has resulted in a broad AMA against a wide range of Gram-positive and resistant Gram-negative bacteria (Ahire et al., 2015). These promising results may represent a new therapeutic alternative to conventional wound dressing materials, especially against antibiotic-resistant microorganisms.

 Conclusion

Bacteriocins are a promising substitute for the currently existing antibiotics that are becoming less effective in the face of the increasing abundance of resistant organisms. However, there are several limitations that challenge the use of bacteriocins as biopreservatives / antibacterial agents in the food and pharmaceutical industries. Nanodelivery systems, such as lipid-, carbohydrate-, metal-, and polymer-based nanoparticles represent promising approaches to maximize the use of these antimicrobial peptides. Several examples of nanoformulated bacteriocins have been shown to possess better stability and a broader spectrum of antimicrobial activity in comparison with the free ones. In conclusion, nanotechnological approaches provide an interesting option toward the formulation of these antimicrobial peptides at the industry-scale level.

 Future perspectives

Bacteriocins have proven their efficiency as antibacterial agents, which explains the currently available examples of these peptides that have been commercially approved for application in the food industry. On the other hand, exploitation of bacteriocins in the health care and pharmaceutical industries is moving forward less rapidly, which is a result of a number of limitations and challenges that have yet to be solved. One of the strategies to overcome these limitations is to apply nanotechnological approaches to enhance the applicability of bacteriocins, increase their stability, and extend their antimicrobial spectrum of activity. While the different approaches to produce these formulations include encapsulation and nanomaterials conjugation, each of these approaches has its own challenges, which need to be addressed to ensure practicality of the approach. More studies are also needed to clarify whether the use of other nanodelivery systems (such as carbon nanotubes) or the combinations with nanoparticles exhibiting AMA (such as zinc oxide) could enhance the antimicrobial properties of bacteriocins. Additionally, the nature of interactions between these peptides and nanomaterials, as well as the interactions between nanoformulations of these peptides and the targeted microorganisms need to be elucidated. Further studies are also required to assess the in vivo efficiency and the safety of these peptides. A better understanding of these areas will pave the way toward more clinical applications of bacteriocins in the near future.

 Author contributions

HF drafted the manuscript. AK and AE revised and approved the final manuscript.

 Funding

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the creation of this manuscript.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 References Ahire J. J. Dicks L. M. (2015). Nisin incorporated with 2, 3-dihydroxybenzoic acid in nanofibers inhibits biofilm formation by a methicillin-resistant strain of Staphylococcus aureus. Probiotics Antimicrob. Proteins 7, 52–59. 10.1007/s12602-014-9171-525319566 Ahire J. J. Neveling D. P. Dicks L. M. (2015). Co-spinning of silver nanoparticles with nisin increases the antimicrobial spectrum of PDLLA: PEO nanofibers. Curr. Microbiol. 71, 24–30. 10.1007/s00284-015-0813-y25855302 Allémann E. Leroux J.-C. Gurny R. (1998). Polymeric nano-and microparticles for the oral delivery of peptides and peptidomimetics. Adv. Drug Deliv. Rev. 34, 171–189. 10.1016/S0169-409X(98)00039-810837677 Anton F. (1934). Process and Apparatus for Preparing Artificial Threads. Google Patents. Arthur T. D. Cavera V. L. Chikindas M. L. (2014). On bacteriocin delivery systems and potential applications. Future Microbiol. 9, 235–248. 10.2217/fmb.13.14824571075 Athanasiou K. A. Niederauer G. G. Agrawal C. M. (1996). Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 17, 93–102. 10.1016/0142-9612(96)85754-18624401 Balciunas E. M. Martinez F. A. C. Todorov S. D. de Melo Franco B. D. G. Converti A. de Souza Oliveira R. P. (2013). Novel biotechnological applications of bacteriocins: a review. Food Control 32, 134–142. 10.1016/j.foodcont.2012.11.025 Banerjee R. (2001). Liposomes: applications in medicine. J. Biomater. Appl. 16, 3–21. 10.1106/RA7U-1V9C-RV7C-8QXL11475357 Bangham A. D. Standish M. M. Watkins J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13, 238–252. 10.1016/S0022-2836(65)80093-65859039 Bernela M. Kaur P. Chopra M. Thakur R. (2014). Synthesis, characterization of nisin loaded alginate–chitosan–pluronic composite nanoparticles and evaluation against microbes. LWT Food Sci. Technol. 59, 1093–1099. 10.1016/j.lwt.2014.05.061 Bi L. Yang L. Bhunia A. K. Yao Y. (2011b). Carbohydrate nanoparticle−mediated colloidal assembly for prolonged efficacy of bacteriocin against food pathogen. Biotechnol. Bioeng. 108, 1529–1536. 10.1002/bit.2309921337333 Bi L. Yang L. Narsimhan G. Bhunia A. K. Yao Y. (2011a). Designing carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide. J. Control. Release 150, 150–156. 10.1016/j.jconrel.2010.11.02421115078 Bradshaw J. P. (2003). Cationic antimicrobial peptides. BioDrugs 17, 233–240. 10.2165/00063030-200317040-0000212899640 Brandelli A. (2012). Nanostructures as promising tools for delivery of antimicrobial peptides. Mini Rev. Med. Chem. 12, 731–741. 10.2174/13895571280126477422512554 Carolissen-Mackay V. Arendse G. Hastings J. W. (1997). Purification of bacteriocins of lactic acid bacteria: problems and pointers. Int. J. Food Microbiol. 34, 1–16. 10.1016/S0168-1605(96)01167-19029252 Castellano P. Aristoy M. C. Sentandreu M. A. Vignolo G. Toldrá F. (2012). Lactobacillus sakei CRL1862 improves safety and protein hydrolysis in meat systems. J. Appl. Microbiol. 113, 1407–1416. 10.1111/jam.1200522963007 Chen H. Narsimhan G. Yao Y. (2015). Particulate structure of phytoglycogen studied using beta-amylolysis. Carbohydr. Polym. 132, 582–588. 10.1016/j.carbpol.2015.06.07426256385 Chen W.-S. Soucie W. G. (1985). Edible Fibrous Serum Milk Protein/Xanthan Gum Complexes. Google Patents. Chopra M. Kaur P. Bernela M. Thakur R. (2014). Surfactant assisted nisin loaded chitosan-carageenan nanocapsule synthesis for controlling food pathogens. Food Control 37, 158–164. 10.1016/j.foodcont.2013.09.024 Chou L. Y. Ming K. Chan W. C. (2011). Strategies for the intracellular delivery of nanoparticles. Chem. Soc. Rev. 40, 233–245. 10.1039/C0CS00003E20886124 Colas J.-C. Shi W. Rao V. M. Omri A. Mozafari M. R. Singh H. (2007). Microscopical investigations of nisin-loaded nanoliposomes prepared by Mozafari method and their bacterial targeting. Micron 38, 841–847. 10.1016/j.micron.2007.06.01317689087 Dankovich T. A. Gray D. G. (2011). Bactericidal paper impregnated with silver nanoparticles for point-of-use water treatment. Environ. Sci. Technol. 45, 1992–1998. 10.1021/es103302t21314116 da Silva Malheiros P. Daroit D. J. da Silveira N. P. Brandelli A. (2010b). Effect of nanovesicle-encapsulated nisin on growth of Listeria monocytogenes in milk. Food Microbiol. 27, 175–178. 10.1016/j.fm.2009.09.01319913710 da Silva Malheiros P. Micheletto Y. M. S. da Silveira N. P. Brandelli A. (2010a). Development and characterization of phosphatidylcholine nanovesicles containing the antimicrobial peptide nisin. Food Res. Int. 43, 1198–1203. 10.1016/j.foodres.2010.02.015 da Silva Malheiros P. Sant'Anna V. Micheletto Y. M. S. da Silveira N. P. Brandelli A. (2011). Nanovesicle encapsulation of antimicrobial peptide P34: physicochemical characterization and mode of action on Listeria monocytogenes. J. Nanoparticle Res. 13, 3545–3552. 10.1007/s11051-011-0278-2 da Silva Malheiros P. Sant'Anna V. Utpott M. Brandelli A. (2012a). Antilisterial activity and stability of nanovesicle-encapsulated antimicrobial peptide P34 in milk. Food Control 23, 42–47. 10.1016/j.foodcont.2011.06.008 da Silva Malheiros P. Sant'Anna V. de Souza Barbosa M. Brandelli A. de Melo Franco B. D. G. (2012b). Effect of liposome-encapsulated nisin and bacteriocin-like substance P34 on Listeria monocytogenes growth in Minas frescal cheese. Int. J. Food Microbiol. 156, 272–277. 10.1016/j.ijfoodmicro.2012.04.00422554928 Davidson P. M. Sofos J. N. Branen A. L. (2005). Antimicrobials in Food. Florida, FL: CRC press. Deegan L. H. Cotter P. D. Hill C. Ross P. (2006). Bacteriocins: biological tools for bio-preservation and shelf-life extension. Int. Dairy J. 16, 1058–1071. 10.1016/j.idairyj.2005.10.026 Delves-Brougthon J. (1990). Nisin and its uses as a food preservative. Food Technol. 44, 100–117. de Mello M. B. da Silva Malheiros P. Brandelli A. da Silveira N. P. Jantzen M. M. da Motta Ad S. (2013). Characterization and antilisterial effect of phosphatidylcholine nanovesicles containing the antimicrobial peptide pediocin. Probiotics Antimicrob. Proteins 5, 43–50. 10.1007/s12602-013-9125-326782604 Doshi J. Reneker D. H. (eds.). (1993). Electrospinning process and applications of electrospun fibers, Industry Applications Society Annual Meeting, 1993, Conference Record of the 1993 IEEE (Akronl, OH: IEEE). El-Gendy A. O. Essam T. M. Amin M. A. Ahmed S. H. Nes I. F. (2013). Clinical screening for bacteriocinogenic Enterococcus faecalis isolated from intensive care unit inpatient in Egypt. J. Microb. Biochem. Technol. 4, 161–167. 10.4172/1948-5948.1000089 Farokhzad O. C. Langer R. (2009). Impact of nanotechnology on drug delivery. ACS Nano 3, 16–20. 10.1021/nn900002m19206243 Feng L. Mumper R. J. (2013). A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett. 334, 157–175. 10.1016/j.canlet.2012.07.00622796606 Furno F. Morley K. S. Wong B. Sharp B. L. Arnold P. L. Howdle S. M. . (2004). Silver nanoparticles and polymeric medical devices: a new approach to prevention of infection? J. Antimicrob. Chemother. 54, 1019–1024. 10.1093/jac/dkh47815537697 Ghazarian H. Idoni B. Oppenheimer S. B. (2011). A glycobiology review: carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem. 113, 236–247. 10.1016/j.acthis.2010.02.00420199800 Gundermann K.-J. Schumacher R. (1990). 50th Anniversary of Phospholipid Research (EPL). Bingen am Rhein: Wbn-Verlag. Héchard Y. Sahl H.-G. (2002). Mode of action of modified and unmodified bacteriocins from Gram-positive bacteria. Biochimie 84, 545–557. 10.1016/S0300-9084(02)01417-712423799 Heunis T. D. Botes M. Dicks L. (2010). Encapsulation of Lactobacillus plantarum 423 and its bacteriocin in nanofibers. Probiotics Antimicrob. Proteins 2, 46–51. 10.1007/s12602-009-9024-926780900 Heunis T. Bshena O. Klumperman B. Dicks L. (2011). Release of bacteriocins from nanofibers prepared with combinations of poly (D, L-lactide)(PDLLA) and poly (ethylene oxide)(PEO). Int. J. Mol. Sci. 12, 2158–2173. 10.3390/ijms1204215821731433 Heunis T. D. Smith C. Dicks L. M. (2013). Evaluation of a nisin-eluting nanofiber scaffold to treat Staphylococcus aureus-induced skin infections in mice. Antimicrob. Agents Chemother. 57, 3928–3935. 10.1128/AAC.00622-1323733456 Hoover D. G. Steenson L. R. (2014). Bacteriocins of Lactic Acid Bacteria. San Diego, CA: Academic Press. Ignatius A. A. Claes L. E. (1996). In vitro biocompatibility of bioresorbable polymers: poly (L, DL-lactide) and poly (L-lactide-co-glycolide). Biomaterials 17, 831–839. 10.1016/0142-9612(96)81421-98730968 Jenning V. Gysler A. Schäfer-Korting M. Gohla S. H. (2000). Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur. J. Pharm. Biopharm. 49, 211–218. 10.1016/S0939-6411(99)00075-210799811 Jia Z. Shen D. Xu W. (2001). Synthesis and antibacterial activities of quaternary ammonium salt of chitosan. Carbohydr. Res. 333, 1–6. 10.1016/S0008-6215(01)00112-411423105 Jizomoto H. Kanaoka E. Sugita K. Hirano K. (1993). Gelatin-acacia microcapsules for trapping micro oil droplets containing lipophilic drugs and ready disintegration in the gastrointestinal tract. Pharm. Res. 10, 1115–1122. 10.1023/A:10189518149398415395 Jung D.-S. Bodyfelt F. W. Daeschel M. A. (1992). Influence of fat and emulsifiers on the efficacy of nisin in inhibiting Listeria monocytogenes in fluid milk. J. Dairy Sci. 75, 387–393. 10.3168/jds.S0022-0302(92)77773-X1560132 Kalchayanand N. Sikes T. Dunne C. P. Ray B. (1994). Hydrostatic pressure and electroporation have increased bactericidal efficiency in combination with bacteriocins. Appl. Environ. Microbiol. 60, 4174–4177. 16349445 Klaenhammer T. R. (1993). Genetics of bacteriocins produced by lactic acid bacteria. FEMS Microbiol. Rev. 12, 39–85. 10.1111/j.1574-6976.1993.tb00012.x23153191 Klaessig F. Marrapese M. Abe S. (2011). Current perspectives in nanotechnology terminology and nomenclature, in Nanotechnol Standards, eds Murashov V. Howard J. (New York, NY: Springer), 21–52. Kruszewska D. Sahl H.-G. Bierbaum G. Pag U. Hynes S. O. Ljungh Å. (2004). Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J. Antimicrob. Chemother. 54, 648–653. 10.1093/jac/dkh38715282239 Kulkarni S. B. Betageri G. V. Singh M. (1995). Factors affecting microencapsulation of drugs in liposomes. J. Microencapsul. 12, 229–246. 10.3109/026520495090102927650588 Kuo W.-S. Chang C.-N. Chang Y.-T. Yeh C.-S. (2009). Antimicrobial gold nanorods with dual-modality photodynamic inactivation and hyperthermia. Chem. Commun. 2009, 4853–4855. 10.1039/b907274h Lara H. H. Ayala-Núnez N. V. Turrent C. I. Ld. Padilla C. R. (2010). Bactericidal effect of silver nanoparticles against multidrug-resistant bacteria. World J. Microbiol. Biotechnol. 26, 615–621. 10.1007/s11274-009-0211-3 Lavertu M. Méthot S. Tran-Khanh N. Buschmann M. D. (2006). High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials 27, 4815–4824. 10.1016/j.biomaterials.2006.04.02916725196 Li C. Bai J. Li W. Cai Z. Ouyang F. (2001). Optimization of conditions for bacteriocin extraction in PEG/salt aqueous two−phase systems using statistical experimental designs. Biotechnol. Prog. 17, 366–368. 10.1021/bp000167w11312717 Li F. Li J. Wen X. Zhou S. Tong X. Su P. . (2009). Anti-tumor activity of paclitaxel-loaded chitosan nanoparticles: An in vitro study. Mater. Sci. Eng. C 29, 2392–2397. 10.1016/j.msec.2009.07.001 Liang H.-F. Chen C.-T. Chen S.-C. Kulkarni A. R. Chiu Y.-L. Chen M.-C. . (2006). Paclitaxel-loaded poly (γ-glutamic acid)-poly (lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Biomaterials 27, 2051–2059. 10.1016/j.biomaterials.2005.10.02716307794 Luong-Van E. Grøndahl L. Chua K. N. Leong K. W. Nurcombe V. Cool S. M. (2006). Controlled release of heparin from poly (ε-caprolactone) electrospun fibers. Biomaterials 27, 2042–2050. 10.1016/j.biomaterials.2005.10.02816305806 Malheiros Pd S. Daroit D. J. Brandelli A. (2012). Inhibition of Listeria monocytogenes in minas frescal cheese by free and nanovesicle-encapsulated nisin. Braz. J. Microbiol. 43, 1414–1418. 10.1590/S1517-8382201200040002424031971 Maretschek S. Greiner A. Kissel T. (2008). Electrospun biodegradable nanofiber nonwovens for controlled release of proteins. J. Control. Release 127, 180–187. 10.1016/j.jconrel.2008.01.01118314212 Melamu R. Von Blottnitz H. (2009). A comparison of environmental benefits of transport and electricity applications of carbohydrate derived ethanol and hydrogen. Int. J. Hydrogen Energy 34, 1126–1134. 10.1016/j.ijhydene.2008.11.020 Millette M. Cornut G. Dupont C. Shareck F. Archambault D. Lacroix M. (2008). Capacity of human nisin-and pediocin-producing lactic acid bacteria to reduce intestinal colonization by vancomycin-resistant enterococci. Appl. Environ. Microbiol. 74, 1997–2003. 10.1128/AEM.02150-0718245231 Montville T. Chen Y. (1998). Mechanistic action of pediocin and nisin: recent progress and unresolved questions. Appl. Microbiol. Biotechnol. 50, 511–519. 10.1007/s0025300513289917136 Mossallam S. F. Amer E. I. Diab R. G. (2014). Potentiated anti-microsporidial activity of Lactobacillus acidophilus CH1 bacteriocin using gold nanoparticles. Exp. Parasitol. 144, 14–21. 10.1016/j.exppara.2014.06.00224929146 Mugabe C. Azghani A. O. Omri A. (2005). Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J. Antimicrob. Chemother. 55, 269–271. 10.1093/jac/dkh51815590716 Murata Y. Maeda T. Miyamoto E. Kawashima S. (1993). Preparation of chitosan-reinforced alginate gel beads—effects of chitosan on gel matrix erosion. Int. J. Pharm. 96, 139–145. 10.1016/0378-5173(93)90221-Z Nes I. F. Yoon S. Diep D. B. (2007). Ribosomally synthesiszed antimicrobial peptides (bacteriocins) in lactic acid bacteria: a review. Food Sci. Biotechnol. 16, 675. Nitta S. K. Numata K. (2013). Biopolymer-based nanoparticles for drug/gene delivery and tissue engineering. Int. J. Mol. Sci. 14, 1629–1654. 10.3390/ijms1401162923344060 Oberdörster G. Oberdörster E. Oberdörster J. (2005). Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 113, 823–839. 10.1289/ehp.733916002369 Perez C. Sanchez A. Putnam D. Ting D. Langer R. Alonso M. (2001). Poly (lactic acid)-poly (ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J. Control. Release 75, 211–224. 10.1016/S0168-3659(01)00397-211451511 Perez R. H. Zendo T. Sonomoto K. (2014). Novel bacteriocins from lactic acid bacteria (LAB): various structures and applications. Microb. Cell Fact. 13(Suppl. 1):S3. 10.1186/1475-2859-13-s1-s325186038 Prombutara P. Kulwatthanasal Y. Supaka N. Sramala I. Chareonpornwattana S. (2012). Production of nisin-loaded solid lipid nanoparticles for sustained antimicrobial activity. Food Control 24, 184–190. 10.1016/j.foodcont.2011.09.025 Puri A. Loomis K. Smith B. Lee J.-H. Yavlovich A. Heldman E. . (2009). Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst. 26, 523–580. 10.1615/CritRevTherDrugCarrierSyst.v26.i6.1020402623 Raghupathi K. R. Koodali R. T. Manna A. C. (2011). Size-dependent bacterial growth inhibition and mechanism of antibacterial activity of zinc oxide nanoparticles. Langmuir 27, 4020–4028. 10.1021/la104825u21401066 Richardson S. W. Kolbe H. J. Duncan R. (1999). Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int. J. Pharm. 178, 231–243. 10.1016/S0378-5173(98)00378-010205643 Riley M. A. Wertz J. E. (2002). Bacteriocins: evolution, ecology, and application. Annu. Rev. Microbiol. 56, 117–137. 10.1146/annurev.micro.56.012302.16102412142491 Rujitanaroj P.-O, Pimpha, N. Supaphol P. (2008). Wound-dressing materials with antibacterial activity from electrospun gelatin fiber mats containing silver nanoparticles. Polymer 49, 4723–4732. 10.1016/j.polymer.2008.08.021 Salmaso S. Elvassore N. Bertucco A. Lante A. Caliceti P. (2004). Nisin-loaded poly-l-lactide nano-particles produced by CO2 anti-solvent precipitation for sustained antimicrobial activity. Int. J. Pharm. 287, 163–173. 10.1016/j.ijpharm.2004.09.00315541923 Saraniya A. Jeevaratnam K. (2014). Optimization of nutritional and non-nutritional factors involved for production of antimicrobial compounds from Lactobacillus pentosus SJ65 using response surface methodology. Braz. J. Microbiol. 45, 81–88. 10.1590/S1517-8382201400010001224948917 Schillinger U. Geisen R. Holzapfel W. (1996). Potential of antagonistic microorganisms and bacteriocins for the biological preservation of foods. Trends Food Sci. Technol. 7, 158–164. 10.1016/0924-2244(96)81256-8 Seil J. T. Webster T. J. (2012). Antimicrobial applications of nanotechnology: methods and literature. Int. J. Nanomedicine 7, 2767. 10.2147/IJN.S2480522745541 Sezer A. Akbuga J. (1999). Release characteristics of chitosan treated alginate beads: II. Sustained release of a low molecular drug from chitosan treated alginate beads. J. Microencapsul. 16, 687–696. 10.1080/02652049928917610575621 Sharma R. Singh H. Joshi M. Sharma A. Garg T. Goyal A. K. . (2014). Recent advances in polymeric electrospun nanofibers for drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 31, 187–217. 10.1615/CritRevTherDrugCarrierSyst.201400819324940748 Sharma T. K. Sapra M. Chopra A. Sharma R. Patil S. D. Malik R. K. . (2012). Interaction of bacteriocin-capped silver nanoparticles with food pathogens and their antibacterial effect. Int. J. Green Nanotechnol. 4, 93–110. 10.1080/19430892.2012.678757 Souto E. Mehnert W. Müller R. (2006). Polymorphic behaviour of Compritol® 888 ATO as bulk lipid and as SLN and NLC. J. Microencapsul. 23, 417–433. 10.1080/02652040600612439 Tagg J. R. Dajani A. S. Wannamaker L. W. (1976). Bacteriocins of gram-positive bacteria. Bacteriol. Rev. 40:722. 791239 Taylor T. M. Gaysinsky S. Davidson P. M. Bruce B. D. Weiss J. (2007). Characterization of antimicrobial-bearing liposomes by ζ-potential, vesicle size, and encapsulation efficiency. Food Biophys. 2, 1–9. 10.1007/s11483-007-9023-x Teixeira M. L. dos Santos J. Silveira N. P. Brandelli A. (2008). Phospholipid nanovesicles containing a bacteriocin-like substance for control of Listeria monocytogenes. Innovative Food Sci. Emerg. Technol. 9, 49–53. 10.1016/j.ifset.2007.05.001 Thirumurugan A. Ramachandran S. Gowri A. S. (2013). Combined effect of bacteriocin with gold nanoparticles against food spoiling bacteria-an approach for food packaging material preparation. Int. Food Res. J. 20, 1909–1912. Vemuri S. Rhodes C. (1995). Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm. Acta Helv. 70, 95–111. 10.1016/0031-6865(95)00010-77651973 Vila A. Sánchez A. Janes K. Behrens I. Kissel T. Jato J. L. V. . (2004). Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 57, 123–131. 10.1016/j.ejpb.2003.09.00614729088 Were L. M. Bruce B. D. Davidson P. M. Weiss J. (2003). Size, stability, and entrapment efficiency of phospholipid nanocapsules containing polypeptide antimicrobials. J. Agric. Food Chem. 51, 8073–8079. 10.1021/jf034836814690399 Wolska K. I. Grzes K. Kurek A. (2012). Synergy between novel antimicrobials and conventional antibiotics or bacteriocins. Pol. J. Microbiol. 61, 95–104. 27557837 Yoon K.-Y. Byeon J. H. Park J.-H. Hwang J. (2007). Susceptibility constants of Escherichia coli and Bacillus subtilis to silver and copper nanoparticles. Sci. Total Environ. 373, 572–575. 10.1016/j.scitotenv.2006.11.00717173953 Zacharof M. Lovitt R. (2012). Bacteriocins produced by lactic acid bacteria a review article. APCBEE Procedia 2, 50–56. 10.1016/j.apcbee.2012.06.010 Zacharof M.-P. Coss G. M. Mandale S. J. Lovitt R. W. (2013). Separation of lactobacilli bacteriocins from fermented broths using membranes. Process Biochem. 48, 1252–1261. 10.1016/j.procbio.2013.05.017 Zhang F. Wu X. Chen Y. Lin H. (2009). Application of silver nanoparticles to cotton fabric as an antibacterial textile finish. Fibers Polym. 10, 496–501. 10.1007/s12221-009-0496-8 Zhang N. Li J. Jiang W. Ren C. Li J. Xin J. . (2010). Effective protection and controlled release of insulin by cationic β-cyclodextrin polymers from alginate/chitosan nanoparticles. Int. J. Pharm. 393, 213–219. 10.1016/j.ijpharm.2010.04.00620394813 Zinjarde S. S. (2012). Bio-inspired nanomaterials and their applications as antimicrobial agents. Chron. Young Sci. 3, 74. 10.4103/2229-5186.94314 Zohri M. Alavidjeh M. S. Haririan I. Ardestani M. S. Ebrahimi S. E. S. Sani H. T. . (2010). A comparative study between the antibacterial effect of nisin and nisin-loaded chitosan/alginate nanoparticles on the growth of Staphylococcus aureus in raw and pasteurized milk samples. Probiotics Antimicrob. Proteins 2, 258–266. 10.1007/s12602-010-9047-226781321 Zohri M. Shafiee Alavidjeh M. Mirdamadi S. S. Behmadi H. Hossaini Nasr S. M. Eshghi Gonbaki S. . (2013). Nisin−Loaded chitosan/alginate nanoparticles: a hopeful hybrid biopreservative. J. Food Saf. 33, 40–49. 10.1111/jfs.12021